Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
ATOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $2.31
Previous CloseN/A
Volume314.80K
Average Volume (3M)530.48K
Market Cap
$86.92M
Enterprise Value$48.35M
Total Cash (Recent Filing)$10.25K
Total Debt (Recent Filing)$189.00K
Price to Earnings (P/E)―
Beta1.91
Next Earnings
May 19, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding129,170,000
10 Day Avg. Volume559,507
30 Day Avg. Volume530,479
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.10K
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$5.50Price Target Upside697.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Atossa Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAtossa announced positive full data from its P2 Karisma study evaluating endoxifen in premenopausal women with mammographic breast density.
Efficacy ComparisonOral endoxifen may yield therapeutic value more rapidly than tamoxifen, reaching therapeutically-viable drug concentrations within seven days.
Safety ProfileEndoxifen was well-tolerated: no significant differences in adverse events between 1mg dose and placebo.
Bears Say
Adverse EventsDue to gynecological events observed at the 80 mg dose, the trial was amended to compare 40 mg Z-endoxifen + OFS to exemestane + OFS, using 4-week Ki-67 reduction as the primary endpoint.
CompetitionThe metastatic breast cancer development landscape is competitive, with several late clinical stage second generation oral SERDs in development.
Treatment CompetitionAnalyst believes that the oral SERD space in 2L+ patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.
---
Ownership Overview
7.29% Insiders
8.05% Mutual Funds
0.45% Other Institutional Investors
75.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $0.65 and its highest was $2.31 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $86.92M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is May 19, 2025 which is in 46 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Mar 25, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.023.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 129,170,000 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
---
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (697.10% Upside)
$5.50 (697.10% Upside)
Blogger Sentiment
Bullish
ATOS Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $7.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.45%
12-Months-Change
Fundamentals
Return on Equity
-31.39%
Trailing 12-Months
Asset Growth
-20.58%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
---
ATOS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.Read More>---
ATOS Stock 12 Month Forecast
Average Price Target
$5.50
▲(697.10% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Cyclacel Pharmaceuticals
―
Immunic
―
Affimed
―
Marker Therapeutics
―
Best Analysts Covering ATOS
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-4.32%
reiterated a buy rating 10 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.32% per trade.
---